|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando
Cancer Res Treat.
2017;49(4):937-946. Published online January 6, 2017 DOI:
https://doi.org/10.4143/crt.2016.423
Web of Science 8
Crossref 5
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jongseok Kim, Mauro Orlando, Yoon-Koo Kang
Cancer Res Treat.
2017;49(4):851-868. Published online January 3, 2017 DOI:
https://doi.org/10.4143/crt.2016.176
Web of Science 43
Crossref 38
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
Keunchil Park, Joo-Hang Kim, Eun Kyung Cho, Jin-Hyoung Kang, Jin-Yuan Shih, Annamaria Hayden Zimmermann, Pablo Lee, Ekaterine Alexandris, Tarun Puri, Mauro Orlando
Cancer Res Treat.
2016;48(4):1177-1186. Published online February 22, 2016 DOI:
https://doi.org/10.4143/crt.2015.401
Web of Science 16
Crossref 14
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A
Post Hoc
Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
Jin Hyoung Kang, Myung-Ju Ahn, Dong-Wan Kim, Eun Kyung Cho, Joo-Hang Kim, Sang Won Shin, Xin Wang, Jong Seok Kim, Mauro Orlando, Keunchil Park
Cancer Res Treat.
2016;48(2):458-464. Published online October 14, 2015 DOI:
https://doi.org/10.4143/crt.2015.135
Web of Science 1
Crossref 1
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Dae Ho Lee, Jung Shin Lee, Jie Wang, Te-Chun Hsia, Xin Wang, Jongseok Kim, Mauro Orlando
Cancer Res Treat.
2015;47(4):616-629. Published online November 24, 2014 DOI:
https://doi.org/10.4143/crt.2014.051
Crossref 8
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Dae Ho Lee, Vichien Srimuninnimit, Rebecca Cheng, Xin Wang, Mauro Orlando
Cancer Res Treat.
2015;47(4):549-554. Published online April 29, 2015 DOI:
https://doi.org/10.4143/crt.2014.362
Web of Science 6
Crossref 7
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
James Chin-Hsin Yang, Myung-Ju Ahn, Kazuhiko Nakagawa, Tomohide Tamura, Helen Barraclough, Sotaro Enatsu, Rebecca Cheng, Mauro Orlando
Cancer Res Treat.
2015;47(3):424-435. Published online September 15, 2014 DOI:
https://doi.org/10.4143/crt.2013.266
Web of Science 4
Crossref 4
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
Joon Oh Park, Do-Youn Oh, Chiun Hsu, Jen-Shi Chen, Li-Tzong Chen, Mauro Orlando, Jong Seok Kim, Ho Yeong Lim
Cancer Res Treat.
2015;47(3):343-361. Published online May 18, 2015 DOI:
https://doi.org/10.4143/crt.2014.308
Web of Science 68
Crossref 64
1
Journal Impact Factor 4.6